2018 Novel vaccines targeting dendritic cells by coupling allergoids to mannan
Novel vaccines targeting dendritic cells by coupling allergoids to mannan
Authors: Cristina Benito-Villalvilla · Irene Soria · José Luis Subiza · Oscar Palomares
Abstract:
Allergen-specific immunotherapy (AIT) is the single disease-modifying treatment for allergy. Clinical trials show AIT to be safe and effective for many patients; however, it still faces problems re- lated to efficacy, safety, long treatment duration and low patient adherence. There has been intensive research to develop alternative strategies, including novel administration routes, adjuvants or hypoal- lergenic molecules. Promising results are reported for some of them, but clinical progress is still mod- erate. Allergoids conjugated to nonoxidized man- nan from Saccharomyces cerevisiae have emerged as a novel concept of vaccine targeting dendritic cells (DCs). Preclinical human and animal models demon- strated that allergoids conjugated to mannan enhance allergen uptake, promote healthy responses to aller- gens by inducing Th1 and T regulatory (Treg) cells, and show clinical efficacy in veterinary medicine. Dose-finding phase II clinical trials in humans are currently ongoing. We review the current stage of allergoids conjugated to mannan as next generation vaccines for AIT.
DOI: https://doi.org/10.1007/s40629-018-0069-8
Comentarios
Publicar un comentario